Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Hyperliquid Strategies Inc Common Stock (PURR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Hyperliquid Strategies Inc Common Stock — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B), while Hyperliquid Strategies Inc Common Stock trades at $9.36 (market cap $2.02B). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 4.4× Hyperliquid Strategies Inc Common Stock's market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Hyperliquid Strategies Inc Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Hyperliquid Strategies Inc Common Stock for 6 Days on average.
| KYMR | PURR | |
|---|---|---|
Market Cap | $8.87B | $2.02B |
Volume | 779,107 | 9,119,303 |
Sector | Health | Financials |
52-Week High | $127.31 | $14.09 |
52-Week Low | $55.80 | $3.10 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $8.26B | $1.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PURR trades at $10.23, down 1.63% over 24 hours, with a bullish technical signal despite recent weakness. The stock shows extreme profitability with a net income margin of 3,229.83% and has beaten earnings estimates for three consecutive quarters. Recent news highlights institutional activity and positive analyst coverage, with a consensus price target of $19.80 implying significant upside.
The outlook is positive given strong earnings momentum and unanimous analyst buy ratings, but risks include high revenue concentration and potential volatility from its asset-heavy business model. The stock's low P/E ratio of 3.18 suggests undervaluation if profitability sustains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Hyperliquid Strategies Inc Common Stock
Hyperliquid Strategies is a digital asset treasury company focused on managing a treasury of HYPE tokens, the native digital assets of the Hyperliquid Layer-1 blockchain.
Read more on PURR →
